Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]

Group 1: Market Performance and Growth - The STAR Market has shown significant vitality since September, with companies like Chipone Technology (688521.SH) expected to achieve a record quarterly revenue of 1.284 billion yuan in Q3 2025, marking a substantial increase of 119.74% quarter-on-quarter and 78.77% year-on-year [1] - In the first half of 2025, 589 companies on the STAR Market collectively generated revenues of 701.4 billion yuan, reflecting a year-on-year growth of 5%. Excluding four major photovoltaic companies, the revenue growth was 12% [3] Group 2: Research and Development Advancements - Multiple companies have reported significant R&D breakthroughs, including DiAo Microelectronics (688381.SH) with its eUSB repeater product, and Guoxin Technology (688262.SH) successfully testing a new generation automotive electronic chip [1] - The STAR Market's overall R&D investment exceeded 84.1 billion yuan in the first half of 2025, which is 2.8 times the net profit, with a median R&D investment ratio of 12.61% [3] Group 3: Biopharmaceutical Innovations - In the biopharmaceutical sector, companies like Sunshine Nuohuo (688621.SH) and Baike Biotechnology (688276.SH) received clinical trial approvals for innovative projects, enhancing their product pipelines [2] - BeiGene (688235.SH) is projected to achieve nearly 19 billion yuan in global sales for its drug Zebrutinib in 2024, indicating strong market potential [4] Group 4: Corporate Confidence and Share Buybacks - Seven companies, including Canray Technology (688061.SH), announced share buyback plans totaling up to 225 million yuan, reflecting strong corporate confidence [2] - Since the beginning of 2025, 72 companies have disclosed 76 buyback plans with a total proposed amount exceeding 6.6 billion yuan, indicating a robust trend in corporate buybacks [4] Group 5: Industry Structure and Competitive Landscape - The STAR Market has established a "chain-group" development pattern, with over 120 companies in the integrated circuit sector covering the entire industry chain, representing more than 60% of A-share companies in the same field [2] - The hard technology sector is transitioning from a follower to a leader, with significant breakthroughs in key areas such as semiconductor equipment and biopharmaceuticals [4]

Summary of New Stock Offerings from October 13 to October 17 Core Viewpoint A total of five new stocks will be available for subscription in the upcoming week, covering industries such as home furnishings, pharmaceutical manufacturing, and computer communication equipment. Notable companies include Marco Polo, a leader in the domestic ceramic tile industry, and Heyuan Bio, a pioneer in the large-scale production of pharmaceutical proteins using rice embryo cell bioreactors. Group 1: Marco Polo - Marco Polo is the leading company in the domestic ceramic tile industry, with its "Marco Polo Tile" brand value ranking first in the industry for over a decade [2] - The company has a total market value of 14.79 billion, with an issuance price-to-earnings ratio of 14.27, significantly lower than the industry average of 32.2 [2] Group 2: Heyuan Bio - Heyuan Bio is recognized as the first in China to utilize rice embryo cell bioreactors for the large-scale production of pharmaceutical proteins, referred to as "rice hematopoiesis" [3] - The company is set to have its human albumin injection HY1001 approved by July 2025 [3] Group 3: Super Electronics - Super Electronics is a major global supplier of automotive electronic PCBs, covering the demand for PCBs across various parts of vehicles [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 4: Xi'an Yicai - Xi'an Yicai has developed into the largest producer and seller of 12-inch silicon wafers in mainland China, ranking sixth globally [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 5: Bibet - Bibet focuses on the independent research and development of innovative drugs, targeting major diseases such as tumors, autoimmune diseases, and metabolic diseases [4] - The company operates in the pharmaceutical manufacturing industry [4]

策 略 研 究 新股分析 2025 年 10 月 10 日 必贝特：拥有全球首创小分子双靶点 抑制剂 ——注册制新股纵览 20251010 本期投资提示： 证 券 研 究 证券分析师 彭文玉 A0230517080001 pengwy@swsresearch.com 朱敏 A0230524050004 zhumin@swsresearch.com 任奕璇 A0230525050002 renyx2@swsresearch.com 联系人 朱敏 (8621)23297818× zhumin@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 申 购 策 略 报 告 相关研究 - ⚫ AHP 得分：剔除、考虑流动性溢价因素后，我们测算必贝特 AHP 得分为 2.02 分、2.02 分， 分别位于科创体系 AHP 模型总分 32.9%分位、36.2%分位，均处于下游偏下水平。 ⚫ 本次网下发行采取约定限售方式：A₁类限售期 9 个月、限售比例 60%，A₂类、A₃类及 B 类 限售期均为 6 个月，限售比例分别为 40%、20%、20%，对应配 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-54 迪哲（江苏）医药股份有限公司 向特定对象发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为向特定对象发行股份；股票认购方式为网 下，上市股数为41,764,808股。 本次股票上市流通总数为41,764,808股。 本次股票上市流通日期为2025 年 10 月 20 日。 一、本次上市流通的限售股类型 2025 年 2 月 8 日，迪哲（江苏）医药股份有限公司（以下简称"公司"）公告 收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意迪哲（江 苏）医药股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕171 号），同意公司向特定对象发行股票的注册申请。 本次发行最终获配发行对象共计 14 名，新增股份 41,764,808 股于 2025 年 4 月 18 日在中国证券登记结算有限责任公司上海分公司办理完成登记、托管及限售 手续。本次发行新增股份为有限售条件流通股，限 ...

华泰联合证券有限责任公司关于 迪哲（江苏）医药股份有限公司 向特定对象发行股票限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"保荐机构"）作为迪 哲（江苏）医药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向 特定对象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》以及《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关规定履行持续督导职责，对迪哲医药 向特定对象发行股票限售股上市流通事项进行了核查，核查的具体情况如下： 一、本次上市流通的限售股类型 2025 年 2 月 8 日，公司公告收到中国证券监督管理委员会（以下简称"中 国证监会"）出具的《关于同意迪哲（江苏）医药股份有限公司向特定对象发行 股票注册的批复》（证监许可〔2025〕171 号），同意公司向特定对象发行股票的 注册申请。 本次发行最终获配发行对象共计 14 名，新增股份 41,764,808 股于 2025 年 4 月 18 日在中国证券登记结算有限责任公司上海分公司办理完成登记、托管及限 售手续。本次发行新增股份为有限售 ...

Investment Rating - The industry rating is "Positive" (maintained) [7] Core Views - The report highlights that the domestic innovative drug sector is entering a phase of "engineer dividend" realization, with improved profitability and valuation breakthroughs expected [1] - The CXO sector is showing signs of recovery, with a positive outlook on CDMO commercialization orders and clinical CRO investment opportunities [2] - The upstream research sector is anticipated to benefit from a downward interest rate cycle and a recovery in global new drug development demand, with recommended stocks including Haoyuan Pharmaceutical and Bid Pharma [3] - The medical device sector is expected to experience a recovery cycle, particularly for high-value consumables and medical equipment companies, with recommendations for companies like Aikang Medical and Mindray Medical [4] - The traditional Chinese medicine sector is projected to see an earnings inflection point, with a favorable outlook for the second half of 2025 [5] - The report favors leading pharmacy chains with superior management capabilities, recommending companies such as Dazhonglin and Yifeng Pharmacy [6] - The pharmaceutical distribution sector is expected to improve, with a focus on low-positioned value and innovative business opportunities [7] Summary by Sections Innovative Drugs - Positive outlook on profitability improvement and valuation breakthroughs due to recognition by multinational corporations [1] CXO - Recovery in the sector with ongoing commercialization of small and large molecule CDMO orders [2] Upstream Research - Anticipated performance elasticity and new business expansion opportunities [3] Medical Devices - Significant growth potential in high-value consumables and medical equipment sectors [4] Traditional Chinese Medicine - Expected earnings growth and increased market interest due to improved fundamentals [5] Pharmacies - Favorable view on pharmacy chains with strong management and adaptability [6] Pharmaceutical Distribution - Positive trends in the sector with potential for operational improvements and value re-evaluation [7]

Core Insights - The unexpected support for a rate cut from two hawkish Federal Reserve members signals a shift in monetary policy dynamics, emphasizing the importance of maintaining the independence of the central bank amidst political pressures [3][4][9] - Market reactions to news often diverge from conventional expectations, highlighting the phenomenon of "buy the rumor, sell the news," where institutional investors act ahead of public sentiment [3][7][9] Group 1: Federal Reserve Actions - The Federal Reserve's decision to cut rates by 25 basis points aligns with market expectations, but the dissenting vote from new member Stephen Miran stands out [3] - The support for a rate cut from hawkish members Waller and Bowman, despite political pressure for lower rates, indicates a commitment to policy independence [4][9] Group 2: Market Behavior - The market's reaction to the news of the rate cut was more pronounced than the cut itself, with Waller's odds dropping and Miran's odds rising significantly [1][3] - Historical patterns show that when positive news is anticipated, institutional investors often position themselves beforehand, leading to a disconnect between market sentiment and actual trading behavior [7][9] Group 3: Investment Strategies - Observing trading volumes, price elasticity, and fund flows can provide critical insights into market sentiment and potential investment opportunities [12] - A focus on behavioral finance principles suggests that when the majority moves in one direction, it may indicate an opportunity in the opposite direction [12]

Market Performance - On October 1, U.S. stock markets initially dropped due to the government shutdown but later rebounded, with the Dow Jones index rising 0.09% to a record high, the S&P 500 increasing by 0.34%, and the Nasdaq Composite gaining 0.42% [1] - Chinese assets strengthened, with the Nasdaq Golden Dragon China Index up 1.44%. Most popular Chinese concept stocks saw gains, including Vipshop up 5.36%, Baidu up 4.3%, JD.com up 3.4%, Alibaba up 2.25%, Pinduoduo up 1.69%, Xpeng up 1.11%, and Li Auto up 0.63% [1] Stock Unlocking Events - In October, 107 stocks are facing unlocking events, with a total market value of 240.73 billion yuan based on the latest closing prices, indicating lower unlocking pressure compared to July, August, and September [2] - Three stocks have unlocking values exceeding 10 billion yuan: China Merchants Port with 577 million shares unlocking, valued at 11.546 billion yuan; Meihua Medical with 412 million shares unlocking, valued at 10.324 billion yuan; and Hengshuai Co. [2][3] Unlocking Ratios and Performance - 25 stocks have unlocking ratios exceeding 50%, with seven stocks, including Arrow Home, Ousheng Electric, Sanbai Shuo, and Meino Energy, having ratios above 70% [4] - Conversely, 24 stocks, including Shengquan Group and Baoding Technology, have relatively low unlocking pressure, with unlocking values below 10 million yuan [7] Performance of Unlocking Stocks - Among the unlocking stocks, 22 reported losses in the first half of the year. The average stock price of unlocking stocks increased by 2.84% since September [8] - Demingli saw the highest price increase, with a 117.02% rise since September, while Zhongke Jincai experienced the largest decline, down 29.55% [8] Institutional Research and Future Prospects - 20 unlocking stocks were researched by institutions in September, with 14 stocks having more than 10 institutional inquiries. Ruide Intelligent received 50 inquiries and has a market value of 5.97 billion yuan facing unlocking [9] - Future growth areas for Ruide include pet technology, healthcare, low-altitude flight, smart home, and robotics, while Fuchuang Precision, with 44 institutional inquiries, has a market value of 9.582 billion yuan facing unlocking [9]

Market Performance - On October 1, U.S. stock markets initially dropped due to the government shutdown but later rebounded, with the Dow Jones index closing up 0.09%, reaching a historical high [1] - The S&P 500 index increased by 0.34%, and the Nasdaq Composite index rose by 0.42% [1] Chinese Stocks - The Nasdaq China Golden Dragon Index rose by 1.44%, with most popular Chinese concept stocks experiencing gains [3] - Notable stock performances include Vipshop up 5.36%, Baidu up 4.3%, JD.com up 3.4%, Alibaba up 2.25%, Pinduoduo up 1.69%, Xpeng Motors up 1.11%, and Li Auto up 0.63% [3] Stock Unlocking Events - In October, 107 stocks are facing unlocking events, with a total market value of 240.73 billion yuan, which is lower than the unlocking pressure in July, August, and September [4] - Three stocks have unlocking values exceeding 10 billion yuan: China Merchants Port (11.55 billion yuan), Meihua Medical (10.32 billion yuan), and Hengshuai Co. (10.31 billion yuan) [6] Performance of Unlocking Stocks - Among the unlocking stocks, 22 reported losses in the first half of the year, with notable declines in companies like Dizh Medical-U and Baiwei Storage [11] - The average stock price of unlocking stocks increased by 2.84% since September, with Demingli leading with a 117.02% increase [10] Institutional Research - 20 unlocking stocks were researched by institutions in September, with 14 stocks having more than 10 institutional inquiries [11] - Companies like Ruide Intelligent and Fuchuang Precision received significant attention, with Ruide Intelligent focusing on the pet economy and Fuchuang Precision achieving breakthroughs in heating plate technology [11]